ReviewBiomolecules2019
A Stage-Based Approach to Therapy in Parkinson's Disease.
Review in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of boxing interventions on physical fitness and health-related quality of life in older people with Parkinson's disease: a systematic review with meta-analysis.Frontiers in public health · 2025Pooled it
- Transcranial Pulse Stimulation Enhances Dexterity in Parkinson's Disease: A Randomized Sham-Controlled Trial.Movement disorders : official journal of the Movement Disorder Society · 2026Trial
- Multi-modal deep learning framework for early detection of Parkinson's disease using neurological and physiological data for high-fidelity diagnosis.Scientific reports · 2025Article
- Time to add two new disorders to neuropsychiatric aspects of Parkinson's disease.Clinical parkinsonism & related disorders · 2025Review
- Psychiatric Disorders and Cognitive Fluctuations in Parkinson's Disease: Changing Approaches in the First Decades of the 21st Century.Brain sciences · 2024Review
- Ketone ester-enriched diet ameliorates motor and dopamine release deficits in MitoPark mice.The European journal of neuroscience · 2024Article
- Sex-dependent associations of serum BDNF, glycolipid metabolism and cognitive impairments in Parkinson's disease with depression: a comprehensive analysis.Journal of neural transmission (Vienna, Austria : 1996) · 2024Article
- The Potentiality of Natural Products and Herbal Medicine as Novel Medications for Parkinson's Disease: A Promising Therapeutic Approach.International journal of molecular sciences · 2024Review
- The central role of the Thalamus in psychosis, lessons from neurodegenerative diseases and psychedelics.Translational psychiatry · 2023Review
- Research progress on the kynurenine pathway in the prevention and treatment of Parkinson's disease.Journal of enzyme inhibition and medicinal chemistry · 2023Review
- Neurotrophic factor-based pharmacological approaches in neurological disorders.Neural regeneration research · 2023Review
- Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson's and Alzheimer's Disease.Biomedicines · 2023Review
- Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease.Arquivos de neuro-psiquiatria · 2023Article
- Effect of citronellol on oxidative stress, neuroinflammation and autophagy pathways in anHeliyon · 2022Article
- Anodal Transcranial Direct Current Stimulation Could Modulate Cortical Excitability and the Central Cholinergic System in Akinetic Rigid-Type Parkinson's Disease: Pilot Study.Frontiers in neurology · 2022Article
- Advances in Parkinson's Disease Drugs.Biomolecules · 2021Article
- Promising drug targets and associated therapeutic interventions in Parkinson's disease.Neural regeneration research · 2021Review
- Enhanced Delivery of Neuroactive Drugs via Nasal Delivery with a Self-Healing Supramolecular Gel.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Serum BDNF discriminates Parkinson's disease patients with depression from without depression and reflect motor severity and gender differences.Journal of neurology · 2021Article
- Dl-3-n-Butylphthalide Alleviates Behavioral and Cognitive Symptoms Via Modulating Mitochondrial Dynamics in the A53T-α-Synuclein Mouse Model of Parkinson's Disease.Frontiers in neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder that features progressive, disabling motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances, and cognitive impairment can present, and they often become a heavy burden for both patients and caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and non-pharmaceutical treatments represent the best therapeutic options to improve quality of life in PD patients. The aim of the present review is to provide a practical, stage-based guide to pharmacological management of both motor and non-motor symptoms of PD. Furthermore, warning about drug side effects, contraindications, as well as dosage and methods of administration, are highlighted here, to help the physician in yielding the best therapeutic strategies for each symptom and condition in patients with PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.